DZD-8586 by Dizal Pharmaceutical for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2024
DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).
Let's personalize your content